This content is from: Capital Markets

Rule change in HK to usher in wave of US IPOs

Changes allowing pre-revenue companies to list on the HKEx means that a number of biotech companies are likely to list on the exchange

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an IFLR subscriber? Login here

Instant access to all of our content. Membership Options | 30 Day Trial